Arformoterol

Arformoterol
Clinical data
Trade names	Brovana
Other names	Arformoterol tartrate (USAN US)
AHFS/Drugs.com	Monograph
MedlinePlus	a602023
License data	US DailyMed: Arformoterol;
Routes of; administration	Inhalation
ATC code	None;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Protein binding	52–65%
Elimination half-life	26 hours
Identifiers
	IUPAC name N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl) propan-2-yl]amino]ethyl] phenyl]formamide;
CAS Number	67346-49-0 ;
PubChem CID	3083544;
IUPHAR/BPS	7479;
DrugBank	DB01274 ;
ChemSpider	2340731 ;
UNII	F91H02EBWT;
KEGG	D07463; D02981;
ChEBI	CHEBI:408174 ;
ChEMBL	ChEMBL1201137 ;
CompTox Dashboard (EPA)	DTXSID1023077 DTXSID40110071, DTXSID1023077 ;
Chemical and physical data
Formula	C19H24N2O4
Molar mass	344.411 g·mol−1
	InChI InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1 ; Key:BPZSYCZIITTYBL-YJYMSZOUSA-N ;
	(what is this?) (verify)

Arformoterol, sold under the brand name Brovana among others, is a medication used for the treatment of chronic obstructive pulmonary disease (COPD).^[1]^[2]

It is a long-acting β₂ adrenoreceptor agonist (LABA) and it is the active (R,R)-(−)-enantiomer of formoterol.^[1] It was approved for medical use in the United States in October 2006.^[1] It is available as a generic medication.^[3]

Medical uses

Arformoterol is indicated for the maintenance treatment of bronchoconstriction in people with chronic obstructive pulmonary disease (COPD).^[1]

References

^ ^a ^b ^c ^d ^e "Brovana- arformoterol tartrate solution". DailyMed. 13 May 2021. Retrieved 4 March 2022.
^ Loh CH, Donohue JF, Ohar JA (March 2015). "Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease". Expert Opinion on Drug Safety. 14 (3): 463–72. doi:10.1517/14740338.2015.998196. PMID 25563342. S2CID 7767810.
^ "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.

External links

"Arformoterol". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on June 15, 2021.
"Arformoterol tartrate". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on March 5, 2022.

[Brovana_FDA_label-1] "Brovana- arformoterol tartrate solution". DailyMed. 13 May 2021. Retrieved 4 March 2022.

[Loh_2015-2] Loh CH, Donohue JF, Ohar JA (March 2015). "Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease". Expert Opinion on Drug Safety. 14 (3): 463–72. doi:10.1517/14740338.2015.998196. PMID 25563342. S2CID 7767810.

[3] "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.

[1]

[2]

[3]